Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

Bleb Vascularity Clinical Trial

Official title:

Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00815594
• Other study ID #: 2008TR-LX-001
• Status: Active, not recruiting
• Phase: Phase 4
• First received: December 29, 2008
• Last updated: December 29, 2008
• Start date: December 2008
• Est. completion date: May 2009

Study information

• Verified date: December 2008
• Source: Capital Medical University
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: May 2009
• Est. primary completion date: March 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Glaucoma patients after trabeculectomy whose bleb is hyperaemia

Exclusion Criteria:

• Affected eye has normal IOP

• Not allergic with Avastin

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bleb Vascularity
• Conjunctival Scarring

Intervention

Drug:
• bevacizumab
0.05ml, 1.25mg

Locations

Country	Name	City	State
China	Tongren hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Capital Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	bleb vascular change		one day, one week, one month	No